NCT00004578 - ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions

HIV Infections

Interventions

DRUG

Lopinavir/Ritonavir

Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs

DRUG

Lamivudine

150 mg, every 12 hours

DRUG

Stavudine

40 mg every 12 hours

Trial Locations (10)

Cornell Clinical Trials Unit - Chelsea Center, New York

University of North Carolina at Chapel Hill, Chapel Hill

Duke University Medical Center, Durham

AIDS Research Consortium of Atlanta, Atlanta

Northwestern University Medical School, Chicago

Rush-Presbyterian-St. Luke's Medical Center, Chicago

Baylor College of Medicine, Houston

University of Colorado Health Sciences Center, Denver

Pacific Oaks Research, Beverly Hills

Beth Israel Deaconess Medical Center, Boston